

CPT[®] Category I New SARS-CoV-2 Vaccine Codes Medium Descriptors

Most recent changes to the CPT[®] Category I New SARS-CoV-2 Vaccine Codes Medium Descriptor document

 Addition of 2 Category 1 codes (0094A and 91309) accepted by the CPT Editorial Panel. Codes 0094A, 91309 and all related references will be published in CPT 2023.

It is important to note that further CPT Editorial Panel or Executive Committee actions may affect these codes and/or descriptors. For this reason, code numbers and/or descriptor language in the CPT code set may differ at the time of publication. In addition, further Panel actions may result in gaps in code number sequencing.

The following codes were accepted by the CPT Editorial Panel. Codes 0001A, 0002A, and 91300 are effective December 11, 2020. Codes 0011A, 0012A, and 91301 are effective December 18, 2020. Codes 0031A and 91303 are effective February 27, 2021. Revised code 0031A is effective October 20, 2021. 0003A and 0013A are effective August 12, 2021. Code 0004A is effective on September 22, 2021. Codes 0034A, 0064A, and 91306 are effective October 20, 2021. Codes 0051A, 0052A, 0053A, 0054A, 0071A, 0072A, 91305, and 91307 are effective October 29, 2021. Code 0073A is effective January 3, 2022.

Codes 0021A, 0022A, 0041A, 0042A, 0081A, 0082A, 0094A, 91302, 91304, 91308 and 91309 will be effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration.

Codes	Medium Code Descriptor	Release to AMA Website	Effective	Publication
●0001A	IMM ADMN SARSCOV2 30MCG/0.3ML DIL RECON 1ST DOSE	November 10, 2020	December 11, 2020	CPT [®] 2022
●0002A	IMM ADMN SARSCOV2 30MCG/0.3ML DIL RECON 2ND DOSE	November 10, 2020	December 11, 2020	CPT [®] 2022
●0003A	IMM ADMN SARSCOV2 30MCG/0.3ML DIL RECON 3RD DOSE	July 30, 2021	August 12, 2021	CPT [®] 2023
●0004A	IMM ADMN SARSCOV2 30MCG/0.3ML DIL RECON BST DOSE	September 3, 2021	September 22, 2021	CPT [®] 2023
#●0051A	IMM ADMN SARSCOV2 30MCG/0.3ML TRIS-SUCROSE 1ST	September 3, 2021	October 29, 2021	CPT [®] 2023
#●0052A	IMM ADMN SARSCOV2 30MCG/0.3ML TRIS-SUCROSE 2ND	September 3, 2021	October 29, 2021	CPT [®] 2023
#●0053A	IMM ADMN SARSCOV2 30MCG/0.3ML TRIS-SUCROSE 3RD	September 3, 2021	October 29, 2021	CPT [®] 2023
#●0054A	IMM ADMN SARSCOV2 30MCG/0.3ML TRIS-SUCROSE BST	September 3, 2021	October 29, 2021	CPT [®] 2023
#●0071A	IMM ADMN SARSCOV2 10MCG/0.2ML TRIS-SUCROSE 1ST	October 6, 2021	October 29, 2021	CPT [®] 2023
#●0072A	IMM ADMN SARSCOV2 10MCG/0.2ML TRIS-SUCROSE 2ND	October 6, 2021	October 29, 2021	CPT [®] 2023
#●0073A	IMM ADMN SARSCOV2 10MCG/0.2ML TRIS-SUCROSE 3RD	January 12, 2022	January 3, 2022	CPT [®] 2023
# ● 0081A	IMM ADMN SARSCOV2 3MCG/0.2ML TRIS-SUCROSE 1ST	February 1, 2022	Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration	CPT [®] 2023
# ● 0082A	IMM ADMN SARSCOV2 3MCG/0.2ML TRIS-SUCROSE 2ND	February 1, 2022	Effective upon receiving Emergency Use	CPT [®] 2023



$\mathsf{CPT}^{\mathbb{R}}$ Category I New SARS-CoV-2 Vaccine Codes Medium Descriptors

			Authorization or approval from the Food and Drug Administration	
●0011A	IMM ADMN SARSCOV2 100 MCG/0.5 ML 1ST DOSE	November 10, 2020	December 18, 2020	CPT [®] 2022
●0012A	IMM ADMN SARSCOV2 100 MCG/0.5 ML 2ND DOSE	November 10, 2020	December 18, 2020	CPT [®] 2022
●0013A	IMM ADMN SARSCOV2 100 MCG/0.5 ML 3RD DOSE	August 16, 2021	August 12, 2021	CPT [®] 2023
#●0064A	IMM ADMN SARSCOV2 50 MCG/0.25 ML BOOSTER DOSE	September 3, 2021	October 20, 2021	CPT [®] 2023
# ● 0094A	IMM ADMN SARSCOV2 50 MCG/0.5 ML BOOSTER DOSE	March 7, 2022	Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration	CPT [®] 2023
●0021A	IMM ADMN SARSCOV2 5X10 ¹⁰ VP/0.5 ML 1ST DOSE	December 17, 2020	Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration	CPT [®] 2022
●0022A	IMM ADMN SARSCOV2 5X10 ¹⁰ VP/0.5 ML 2ND DOSE	December 17, 2020	Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration	CPT [®] 2022
		New Code Released to AMA Website:	New Code Effective:	
▲⊕ 0031A	IMM ADMN SARSCOV2 AD26 5X10 ¹⁰ VP/0.5 ML 1 DOSE	January 19, 2021	February 27, 2021	CPT®
		Revised Code Released to AMA Website:	Revised Code Effective: October 20, 2021	2022/2023
		October 27, 2021		
●0034A	IMM ADMN SARSCOV2 AD26 5X10 ¹⁰ VP/0.5 ML BST DOSE	October 27, 2021	October 20, 2021	CPT [®] 2023
●0041A	IMM ADMN SARSCOV2 5 MCG/0.5 ML 1ST DOSE	May 4, 2021	Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration	CPT [®] 2022



$\mathsf{CPT}^{\mathbb{R}}$ Category I New SARS-CoV-2 Vaccine Codes Medium Descriptors

●0042A	IMM ADMN SARSCOV2 5 MCG/0.5 ML 2ND DOSE	May 4, 2021	Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration	CPT [®] 2022
# • 91300	SARSCOV2 VACCINE DIL RECON 30 MCG/0.3 ML IM USE	November 10, 2020	December 11, 2020	CPT [®] 2022
# // ●91305	SARSCOV2 VACCINE 30MCG/0.3ML TRIS-SUCROSE IM USE	September 3, 2021	October 29, 2021	CPT [®] 2023
# // ●91307	SARSCOV2 VACCINE 10MCG/0.2ML TRIS-SUCROSE IM USE	October 6, 2021	October 29, 2021	CPT [®] 2023
#№●91308	SARSCOV2 VACCINE 3MCG/0.2ML TRIS-SUCROSE IM USE	February 1, 2022	Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration	CPT [®] 2023
# • 91301	SARSCOV2 VACCINE 100 MCG/0.5 ML IM USE	November 10, 2020	December 18, 2020	CPT [®] 2022
# ≠ ●91306	SARSCOV2 VACCINE 50 MCG/0.25 ML IM USE	September 3, 2021	October 20, 2021	CPT [®] 2023
# № ● 91309	SARSCOV2 VACCINE 50 MCG/0.5 ML IM USE	March 7, 2022	Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration	CPT [®] 2023
#№●91302	SARSCOV2 VACCINE CHADOX1 5X10 ¹⁰ VP/0.5ML IM USE	December 17, 2020	Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration	CPT [®] 2022
#●91303	SARSCOV2 VACCINE AD26 5X10 ¹⁰ VP/0.5ML IM USE	January 19, 2021	February 27, 2021	CPT [®] 2022
#№●91304	SARSCOV2 VACC SAPONIN-BSD ADJT 5MCG/0.5ML IM USE	May 4, 2021	Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration	CPT [®] 2022